Aussie Biotech Says Millions In Royalties Lost To Medical Institutions
This article was originally published in PharmAsia News
Executive Summary
The Australian biotech Genetic Technologies says publicly funded institutions are violating its patents to the tune of about $12.6 million a year. The company objected to the alleged violations as a Senate panel considered barring patents on genetic intellectual property. Paul MacLeman, CEO of Genetic, which specializes in testing DNA, said the medical institutions screen for breast cancer at commercial rates, but pay no royalties to the owner of the patents for those tests. When Genetic sought to enforce its patents last year, it had to back off after a public outcry. (Click here for more
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.